



## Clinical trial results:

### A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy

#### Summary

EudraCT number	2018-003707-19
Trial protocol	FR DE GB ES IT
Global end of trial date	30 September 2022

#### Results information

Result version number	v1 (current)
This version publication date	01 October 2023
First version publication date	01 October 2023

#### Trial information

##### Trial identification

Sponsor protocol code	MS200647_0047
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03833661
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Merck Healthcare KGaA, Darmstadt, Germany
Sponsor organisation address	Frankfurter Strasse 250, Darmstadt, Germany, 64293
Public contact	Communication Centre, Merck Healthcare KGaA, Darmstadt, Germany, +49 6151725200, service@merckgroup.com
Scientific contact	Communication Centre, Merck Healthcare KGaA, Darmstadt, Germany, +49 6151725200, service@merckgroup.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 September 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 September 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate M7824 monotherapy in subjects with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.

Protection of trial subjects:

Subject protection was ensured by following high medical and ethical standards in accordance with the principles laid down in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and applicable regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 March 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 23
Country: Number of subjects enrolled	France: 15
Country: Number of subjects enrolled	Spain: 17
Country: Number of subjects enrolled	Italy: 19
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Germany: 9
Country: Number of subjects enrolled	Japan: 21
Country: Number of subjects enrolled	Korea, Republic of: 34
Country: Number of subjects enrolled	China: 11
Country: Number of subjects enrolled	Taiwan: 9
Worldwide total number of subjects	159
EEA total number of subjects	60

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	76
From 65 to 84 years	83
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

First subject signed informed consent: 26 Mar 2019, Clinical cutoff date: 30 March 2021.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	M7824
------------------	-------

Arm description:

Subjects received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.

Arm type	Experimental
Investigational medicinal product name	M7824
Investigational medicinal product code	
Other name	Bintrafusp alfa
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

M7824 administered to subjects at a dose of 1200 mg once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.

<b>Number of subjects in period 1</b>	M7824
Started	159
Completed	159

## Baseline characteristics

### Reporting groups

Reporting group title	M7824
-----------------------	-------

Reporting group description:

Subjects received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.

Reporting group values	M7824	Total	
Number of subjects	159	159	
Age categorical			
Units: Subjects			

Age Continuous			
Units: years			
arithmetic mean	64		
standard deviation	± 8.9	-	
Sex: Female, Male			
Units: subjects			
Female	65	65	
Male	94	94	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	77	77	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	0	0	
White	64	64	
More than one race	0	0	
Unknown or Not Reported	18	18	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	4	4	
Not Hispanic or Latino	155	155	
Unknown or Not Reported	0	0	

## End points

### End points reporting groups

Reporting group title	M7824
Reporting group description:	
Subjects received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.	

### Primary: Percentage of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)

End point title	Percentage of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) <sup>[1]</sup>
-----------------	---

#### End point description:

Confirmed objective response was defined as the percentage of subjects with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Confirmed CR = at least 2 determinations of CR at least 4 weeks apart and before progression. Confirmed PR = at least 2 determinations of PR at least 4 weeks apart and before progression (and not qualifying for a CR). Confirmed objective response was determined according to RECIST v1.1 and as adjudicated by IRC. Intention-To-Treat (ITT) analysis set included all subjects who were administered at least one dose of M7824.

End point type	Primary
----------------	---------

#### End point timeframe:

Time from first treatment to data cutoff (assessed up to 736 days)

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical and comparison analysis were performed in single arm for this endpoint.

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	159			
Units: percentage of subjects				
number (confidence interval 95%)	10.7 (6.4 to 16.6)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs, Including Adverse Event of Special Interests (AESIs)

End point title	Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs, Including Adverse Event of Special Interests (AESIs)
-----------------	---

#### End point description:

Adverse Event (AE) was defined any untoward medical occurrence in a subject administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was

defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on-treatment period. TEAEs included serious AEs and non-serious AEs. Treatment-related TEAEs: reasonably related to the study intervention. AESIs included Infusion-related reactions, Immune-related AEs, Transforming growth factor-beta (TGF- $\beta$ ) inhibition mediated skin AE and anemia. Safety analysis set included all subjects who were administered at least one dose of M7824.

End point type	Secondary
End point timeframe:	
Time from first treatment to data cutoff (assessed up to 736 days)	

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	159			
Units: subjects				
TEAEs	152			
Treatment Related TEAEs	99			
AESI: Infusion-related reaction	10			
AESI: Immune-related AE	46			
AESI: TGF- $\beta$ inhibition mediated skin AE	13			
AESI: Anemia	44			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Durable Response Rate (DRR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)

End point title	Durable Response Rate (DRR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)
-----------------	---

End point description:

DRR was defined as the percentage of subjects with confirmed objective response (CR or PR) with duration of at least 6 months. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DRR was determined according to RECIST v1.1 and assessed by IRC. ITT analysis set included all subjects who were administered at least one dose of M7824. Here, "Overall Number of Subjects Analyzed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
Time from first treatment to data cutoff (assessed up to 736 days)	

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: percentage of subjects				
number (confidence interval 95%)	6.3 (3.1 to 11.3)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)

End point title	Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC)
-----------------	--

End point description:

DOR was defined for subjects with confirmed response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was determined according to RECIST v1.1 and assessed by IRC. Results were calculated based on Kaplan-Meier estimates. ITT analysis set was used. "Number of Subjects Analyzed" = subjects who were evaluable for this endpoint. "99.9" = The upper limit could not be estimated due to insufficient number of events by the date of data cutoff.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first documentation of objective response to data cutoff (assessed up to 736 days)

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: months				
median (confidence interval 95%)	10.0 (3.9 to 99.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator

End point title	Percentage of Subjects with Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors
-----------------	--



## End point description:

Confirmed objective response was defined as the percentage of subjects with a confirmed objective response of complete response (CR) or partial response (PR). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Confirmed CR = at least 2 determinations of CR at least 4 weeks apart and before progression. Confirmed PR = at least 2 determinations of PR at least 4 weeks apart and before progression (and not qualifying for a CR). Confirmed objective response was determined according to RECIST v1.1 and as adjudicated by Investigator. ITT analysis set included all subjects who were administered at least one dose of M7824.

End point type	Secondary
----------------	-----------

## End point timeframe:

Time from first treatment to data cutoff (assessed up to 736 days)

End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	159			
Units: percentage of subjects				
number (confidence interval 95%)	10.7 (6.4 to 16.6)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)

End point title	Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)
-----------------	---

## End point description:

PFS was defined as the time from first administration of study intervention until the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. ITT analysis set included all subjects who were administered at least one dose of M7824.

End point type	Secondary
----------------	-----------

## End point timeframe:

Time from first administration of study drug until the first documentation of PD or death, assessed up to data-cutoff (736 days)

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	159			
Units: months				
median (confidence interval 95%)	1.8 (1.7 to 1.8)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator

End point title	Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator
-----------------	--

End point description:

DOR was defined for subjects with confirmed response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was determined according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and assessed by Investigator. Results were calculated based on Kaplan-Meier estimates. ITT analysis set included all subjects who were administered at least one dose of M7824. Here, "Number of Subjects Analyzed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first documentation of objective response to data cutoff (assessed up to 736 days)

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: months				
median (confidence interval 95%)	8.2 (3.9 to 12.0)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Durable Response Rate (DRR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator

End point title	Durable Response Rate (DRR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator
-----------------	---

---

**End point description:**

DRR was defined as the percentage of subjects with confirmed objective response (CR or PR) with duration of at least 6 months. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DRR was determined according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and assessed by Investigator. ITT analysis set included all subjects who were administered at least one dose of M7824. Here, "Number of Subjects Analyzed" signifies those subjects who were evaluable for this endpoint.

---

End point type	Secondary
----------------	-----------

---

**End point timeframe:**

Time from first treatment to data cutoff (assessed up to 736 days)

---

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: percentage of subjects				
number (confidence interval 95%)	5.7 (2.6 to 10.5)			

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator**

---

End point title	Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator
-----------------	---

---

**End point description:**

PFS was defined as the time from first administration of study intervention until the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. ITT analysis set included all subjects who were administered at least one dose of M7824.

---

End point type	Secondary
----------------	-----------

---

**End point timeframe:**

Time from first administration of study drug until the first documentation of PD or death, assessed up to data-cutoff (736 days)

---

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	159			
Units: months				
median (confidence interval 95%)	1.8 (1.7 to 1.8)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from first administration of study intervention to the date of death due to any cause. The OS was analyzed by using the Kaplan-Meier method. ITT analysis set included all subjects who were administered at least one dose of M7824.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first administration of study drug to data cutoff (assessed up to 736 days)

End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	159			
Units: months				
median (confidence interval 95%)	7.6 (5.8 to 9.5)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Pre-Dose Concentrations (Ctrough) of M7824

End point title	Serum Pre-Dose Concentrations (Ctrough) of M7824
-----------------	--

End point description:

Ctrough was defined as the concentration observed immediately before next dosing (corresponding to pre-dose or trough concentration for multiple dosing). Pharmacokinetic (PK) analysis set included all subjects who completed at least one dose of M7824 and who provided at least one sample with a measurable concentration of M7824. Here, "Number of subjects Analyzed" signifies those subjects who were evaluable for this endpoint and "n" signifies those participants who were evaluable at specified time points for this endpoint. Here, "9999"=Geometric Mean and Geometric Coefficient of Variation were not calculated if fewer than 3 subjects have reportable parameter values.

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 15, Day 29, Day 43, Day 85, Day 127, Day 169, Day 253, Day 337, Day 421 and Day 505

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	138			
Units: microgram per milliliter (mcg/mL)				
geometric mean (geometric coefficient of variation)				
Day 15: n = 138	70.7 (± 40.7)			
Day 29: n = 105	84.2 (± 58.0)			
Day 43: n = 89	93.4 (± 52.6)			
Day 85: n = 40	105 (± 42.6)			
Day 127: n = 26	117 (± 41.5)			
Day 169: n = 12	101 (± 55.6)			
Day 253: n = 13	115 (± 46.8)			
Day 337: n = 6	91.3 (± 41.5)			
Day 421: n = 5	114 (± 36.7)			
Day 505: n = 2	9999 (± 9999)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Positive Antidrug Antibodies (ADA)

End point title	Number of Subjects with Positive Antidrug Antibodies (ADA)
-----------------	--

End point description:

Serum samples were analyzed by a validated assay method to detect the presence of antidrug antibodies (ADA). Number of subjects with positive ADA were reported. Immunogenicity analysis set included all subjects who received at least one dose of M7824 and who had at least one valid result of ADA.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first treatment to data cutoff (assessed up to 736 days)

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	157			
Units: subjects	45			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Concentration at End of Infusion (CEOI) of M7824

End point title	Serum Concentration at End of Infusion (CEOI) of M7824
-----------------	--

**End point description:**

Serum Concentration at End of Infusion (CEOI) of M7824 is reported. Pharmacokinetic (PK) analysis set included all subjects who completed at least one dose of M7824 and who provided at least one sample with a measurable concentration of M7824. Here, "Number of subjects Analyzed" signifies those subjects who were evaluable for this endpoint and "n" signifies those subjects who were evaluable at specified time points for this endpoint.

End point type	Secondary
----------------	-----------

**End point timeframe:**

At Day 1 and Day 29

End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	152			
Units: mcg/mL				
geometric mean (geometric coefficient of variation)				
Day 1: n = 152	399 ( $\pm$ 31.5)			
Day 29: n = 104	434 ( $\pm$ 48.5)			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Percentage of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression**

End point title	Percentage of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression
-----------------	--

**End point description:**

Confirmed objective response: percentage of subjects with a confirmed objective response of CR or PR. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Confirmed CR = at least 2 determinations of CR at least 4 weeks apart and before progression. Confirmed PR = at least 2 determinations of PR at least 4 weeks apart and before progression (and not qualifying for a CR). Confirmed objective response was determined according to RECIST v1.1 and as adjudicated by IRC through PD-L1 Subgroup: PD-L1 expression on tumor cells (TC) and on immune cells (IC) at baseline and in the following categories: <1%,  $\geq$ 1%, <5%,  $\geq$ 5%, <25%,  $\geq$ 25%, <50%,  $\geq$ 50% were reported. ITT analysis set was used. "Number of Subjects Analyzed" = subjects who were evaluable for this endpoint and "n" = subjects who were evaluable for the specified categories for this endpoint.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Time from first treatment to data cutoff (assessed up to 736 days)

End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	141			
Units: percentage of subjects				
number (confidence interval 95%)				
PD-L1 expression on TC: < 1%; n = 98	10.2 (5.0 to 18.0)			
PD-L1 expression on TC: >= 1%; n = 43	7.0 (1.5 to 19.1)			
PD-L1 expression on TC: < 5%; n = 113	9.7 (5.0 to 16.8)			
PD-L1 expression on TC: >= 5%; n = 28	7.1 (0.9 to 23.5)			
PD-L1 expression on TC: < 25%; n = 126	8.7 (4.4 to 15.1)			
PD-L1 expression on TC: >= 25%; n = 15	13.3 (1.7 to 40.5)			
PD-L1 expression on TC: < 50%; n = 130	9.2 (4.9 to 15.6)			
PD-L1 expression on TC: >= 50%; n = 11	9.1 (0.2 to 41.3)			
PD-L1 expression on IC: < 1%; n = 22	13.6 (2.9 to 34.9)			
PD-L1 expression on IC: >= 1%; n = 108	7.4 (3.3 to 14.1)			
PD-L1 expression on IC: < 5%; n = 46	8.7 (2.4 to 20.8)			
PD-L1 expression on IC: >= 5%; n = 84	8.3 (3.4 to 16.4)			
PD-L1 expression on IC: < 25%; n = 120	7.5 (3.5 to 13.8)			
PD-L1 expression on IC: >= 25%; n = 10	20.0 (2.5 to 55.6)			
PD-L1 expression on IC: < 50%; n = 129	8.5 (4.3 to 14.7)			
PD-L1 expression on IC: >= 50%; n = 1	0.0 (0.0 to 97.5)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With Confirmed Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) According to Microsatellite instability (MSI) Status

End point title	Percentage of Subjects With Confirmed Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) According to Microsatellite instability (MSI) Status
-----------------	---

End point description:

Confirmed OR: percentage of subjects with a confirmed OR of CR or PR. Confirmed CR: at least 2 determinations of CR at least 4 weeks apart and before progression. Confirmed PR: at least 2 determinations of PR at least 4 weeks apart and before progression (and not qualifying for a CR). Confirmed OR was adjudicated by IRC through MSI Status subgroups as:- MSI High = if subject is MSI High for any (at least one) test;- Microsatellite stable (MSS) or MSI Low = if subject is not MSI High for

any test;- Unknown (missing) = no MSI tests available at baseline was reported. MSI high: if 2 or more unstable markers were detected in sample; MSI low: if 1 marker was unstable and remaining markers were stable and MSS if all markers were stable. ITT analysis set was used. "Number of Subjects Analyzed"=subjects who were evaluable for this endpoint and "n"=subjects who were evaluable for the specified categories for this endpoint. "99999" = None of subjects were evaluable for specified category.

End point type	Secondary
End point timeframe:	
Time from first treatment to data cutoff (assessed up to 736 days)	

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	153			
Units: percentage of subjects				
number (confidence interval 95%)				
High: n = 3	0.0 (0.0 to 70.8)			
Low or Microsatellite stable: n = 150	10.0 (5.7 to 16.0)			
Unknown (missing): n = 0	99999 (99999 to 99999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression

End point title	Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression
-----------------	--

End point description:

DOR: subjects with confirmed response, as time from first documentation of objective response (CR/PR) to date of first documentation of PD/death due to any cause, whichever occurred first. PD: At least a 20% increase in SLD, taking as reference smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was adjudicated by IRC through PD-L1 Subgroup: PD-L1 expression on tumor cells (TC) and on immune cells (IC) at baseline and in following categories: <1%, ≥1%, <5%, ≥5%, <25%, ≥25%, <50%, ≥50% was reported. ITT analysis set was used. "Number of Subjects Analyzed" =subjects who were evaluable for this endpoint; "n"=subjects who were evaluable for the specified categories for this endpoint. "999" = Due to small number of events, Median and Upper limit of 95% Confidence Interval could not derive and "99999" = None of the subjects were evaluable for the specified category.

End point type	Secondary
End point timeframe:	
Time from first documentation of objective response to data cutoff (assessed up to 736 days)	



End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	13			
Units: months				
median (confidence interval 95%)				
PD-L1 expression on TC: < 1%; n = 10	999 (3.4 to 999)			
PD-L1 expression on TC: >= 1%; n = 3	5.8 (3.9 to 999)			
PD-L1 expression on TC: < 5%; n = 11	999 (3.4 to 999)			
PD-L1 expression on TC: >= 5%; n = 2	999 (3.9 to 999)			
PD-L1 expression on TC: < 25%; n = 11	999 (3.4 to 999)			
PD-L1 expression on TC: >= 25%; n = 2	999 (3.9 to 999)			
PD-L1 expression on TC: < 50%; n = 12	999 (3.7 to 999)			
PD-L1 expression on TC: >= 50%; n = 1	999 (999 to 999)			
PD-L1 expression on IC: < 1%; n = 3	999 (3.4 to 999)			
PD-L1 expression on IC: >= 1%; n = 8	999 (3.7 to 999)			
PD-L1 expression on IC: < 5%; n = 4	999 (3.4 to 999)			
PD-L1 expression on IC: >= 5%; n = 7	999 (3.9 to 999)			
PD-L1 expression on IC: < 25%; n = 9	999 (3.4 to 999)			
PD-L1 expression on IC: >= 25%; n = 2	999 (999 to 999)			
PD-L1 expression on IC: < 50%; n = 11	999 (3.4 to 999)			
PD-L1 expression on IC: >= 50%; n = 0	99999 (99999 to 99999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite instability (MSI) Status

End point title	Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite instability (MSI) Status
-----------------	--

End point description:

DOR: participants with confirmed response, as the time from first documentation of objective response (CR/PR) to the date of first documentation of PD or death due to any cause, whichever occurred first. PD: At least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DOR was by IRC through MSI Status subgroups as:- MSI High = if subject is MSI High for any (at least one) test;- MSS or MSI Low = if subject is not MSI High for any test;- Unknown (missing) = no MSI tests available at baseline was reported. ITT analysis set was used. "Number of Subjects Analyzed" = subjects who were evaluable for this endpoint and "n" = subjects who

were evaluable for the specified categories for this endpoint. "999" = Due to small number of events, Median and Upper limit of 95% Confidence Interval could not derive and "99999" = None of the subjects were evaluable for the specified category.

End point type	Secondary
End point timeframe:	
Time from first documentation of objective response to data cutoff (assessed up to 736 days)	

<b>End point values</b>	M7824			
Subject group type	Reporting group			
Number of subjects analysed	15			
Units: months				
median (confidence interval 95%)				
High: n = 0	99999 (99999 to 99999)			
Low or Microsatellite stable: n = 15	999 (3.7 to 999)			
Unknown (missing): n = 0	99999 (99999 to 99999)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Durable Response Rate (DRR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression

End point title	Durable Response Rate (DRR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to Programmed Death Ligand 1 (PD-L1) Expression
-----------------	---

End point description:

DRR was defined as the percentage of subjects with confirmed objective response (CR or PR) with duration of at least 6 months. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DRR was determined according to RECIST v1.1 and adjudicated by IRC through PD-L1 Subgroup: PD-L1 expression on tumor cells (TC) and on immune cells (IC) at baseline and in the following categories: <1%, ≥1%, <5%, ≥5%, <25%, ≥25%, <50%, ≥50% was reported. ITT analysis set was used. "Number of Subjects Analyzed" =subjects who were evaluable for this endpoint and "n" signifies those subjects who were evaluable for the specified categories for this endpoint.

End point type	Secondary
End point timeframe:	
Time from first treatment to data cutoff (assessed up to 736 days)	

End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	141			
Units: percentage of subjects				
number (confidence interval 95%)				
PD-L1 expression on TC: < 1%; n = 98	6.1 (2.3 to 12.9)			
PD-L1 expression on TC: >= 1%; n = 43	2.3 (0.1 to 12.3)			
PD-L1 expression on TC: < 5%; n = 113	5.3 (2.0 to 11.2)			
PD-L1 expression on TC: >= 5%; n = 28	3.6 (0.1 to 18.3)			
PD-L1 expression on TC: < 25%; n = 126	4.8 (1.8 to 10.1)			
PD-L1 expression on TC at >= 25%; n = 15	6.7 (0.2 to 31.9)			
PD-L1 expression on TC: < 50%; n = 130	4.6 (1.7 to 9.8)			
PD-L1 expression on TC: >= 50%; n = 11	9.1 (0.2 to 41.3)			
PD-L1 expression on IC: < 1%; n = 22	9.1 (1.1 to 29.2)			
PD-L1 expression on IC: >= 1%; n = 108	3.7 (1.0 to 9.2)			
PD-L1 expression on IC: < 5%; n = 46	4.3 (0.5 to 14.8)			
PD-L1 expression on IC: >= 5%; n = 84	4.8 (1.3 to 11.7)			
PD-L1 expression on IC: < 25%; n = 120	3.3 (0.9 to 8.3)			
PD-L1 expression on IC: >= 25%; n = 10	20.0 (2.5 to 55.6)			
PD-L1 expression on IC: < 50%; n = 129	4.7 (1.7 to 9.8)			
PD-L1 expression on IC: >= 50%; n = 1	0.0 (0.0 to 97.5)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Durable Response Rate (DRR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to Microsatellite instability (MSI) Status

End point title	Durable Response Rate (DRR) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to Microsatellite instability (MSI) Status
-----------------	--

End point description:

DRR: percentage of subjects with confirmed OR (CR/PR) with duration of at least 6 months. PD: At least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. DRR was determined according to RECIST v1.1 and adjudicated by IRC through MSI Status subgroups as:- MSI High = if subject is MSI High for any (at least one) test;- MSS or MSI Low = if subject is not MSI High for any test;- Unknown (missing) = no MSI tests available at baseline was reported. ITT analysis set included all subjects who were administered at least one dose of M7824. Here, "Number of Subjects Analyzed" signifies those subjects who were evaluable for this

endpoint and "n" signifies those subjects who were evaluable for the specified categories for this endpoint. Here, "99999" = None of subjects were evaluable for specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first treatment to data cutoff (assessed up to 736 days)

End point values	M7824			
Subject group type	Reporting group			
Number of subjects analysed	153			
Units: percentage of subjects				
number (confidence interval 95%)				
High: n = 3	0.0 (0.0 to 70.8)			
Low or Microsatellite stable: n = 150	4.0 (1.5 to 8.5)			
Unknown (missing): n = 0	99999 (99999 to 99999)			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Time from first treatment to data cutoff (assessed up to 736 days)

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	M7824
-----------------------	-------

Reporting group description:

Subjects received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.

Serious adverse events	M7824		
Total subjects affected by serious adverse events			
subjects affected / exposed	86 / 159 (54.09%)		
number of deaths (all causes)	108		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatocellular carcinoma			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Keratoacanthoma			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malignant ascites			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tumour hyperprogression			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Tumour pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tumour necrosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Biliary stent placement			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Disease progression			
subjects affected / exposed	16 / 159 (10.06%)		
occurrences causally related to treatment / all	0 / 16		
deaths causally related to treatment / all	0 / 14		
Fatigue			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			

subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pyrexia			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Pulmonary embolism			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Dyspnoea			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Myocarditis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ventricular fibrillation			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Immune-mediated encephalitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Haemolytic anaemia			



subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Duodenal stenosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dysphagia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric stenosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastritis erosive			

subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal vascular malformation haemorrhagic				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haemorrhoidal haemorrhage				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ileus				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mechanical ileus				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Upper gastrointestinal haemorrhage				

subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Bile duct obstruction			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cholangitis			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 1		
Cholangitis acute			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cholestasis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	1 / 3		
Hepatitis			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatocellular injury			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Jaundice			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Jaundice cholestatic			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Liver injury			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Lichenoid keratosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pemphigoid			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash maculo-papular			

subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Toxic skin eruption			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Nephritis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myositis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abdominal infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Bacterial sepsis				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Biliary tract infection				
subjects affected / exposed	6 / 159 (3.77%)			
occurrences causally related to treatment / all	0 / 6			
deaths causally related to treatment / all	0 / 0			
Bursitis infective				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
COVID-19				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infective spondylitis				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	2 / 159 (1.26%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				
subjects affected / exposed	1 / 159 (0.63%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sepsis				

subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Staphylococcal infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subcutaneous abscess			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Varicella zoster pneumonia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Varicella zoster virus infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular device infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			

subjects affected / exposed	2 / 159 (1.26%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Latent autoimmune diabetes in adults			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	M7824		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	144 / 159 (90.57%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Cancer pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Infected neoplasm			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Keratoacanthoma			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences (all)	8		
Lip squamous cell carcinoma			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Melanocytic naevus			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Seborrhoeic keratosis			



subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Squamous cell carcinoma of skin			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Tumour pain			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Basal cell carcinoma			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Vascular disorders			
Embolism			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Flushing			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Haematoma			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Hot flush			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences (all)	8		
Hypotension			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Phlebitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Orthostatic hypotension			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	23 / 159 (14.47%)		
occurrences (all)	23		
Fatigue			
subjects affected / exposed	23 / 159 (14.47%)		
occurrences (all)	23		
Oedema peripheral			
subjects affected / exposed	11 / 159 (6.92%)		
occurrences (all)	11		
Pyrexia			
subjects affected / exposed	25 / 159 (15.72%)		
occurrences (all)	25		
Chest discomfort			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Chest pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Chills			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Disease progression			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Generalised oedema			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Influenza like illness			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Malaise			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	2		
Mucosal inflammation			

subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Non-cardiac chest pain			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Oedema			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pain			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Mucosal haemorrhage			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Immune system disorders			
Contrast media allergy			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hypersensitivity			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Infusion related hypersensitivity reaction			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Nipple pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Prostatitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pruritus genital			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Scrotal oedema			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences (all)	8		
Epistaxis			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences (all)	8		
Hypoxia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	7 / 159 (4.40%)		
occurrences (all)	7		
Dysphonia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Dyspnoea exertional			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Haemoptysis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pleural effusion			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Productive cough			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pulmonary artery thrombosis			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pulmonary embolism			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Sputum increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pneumonitis			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Delirium			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Depression			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Insomnia			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences (all)	8		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	24 / 159 (15.09%)		
occurrences (all)	24		
Aspartate aminotransferase increased			
subjects affected / exposed	26 / 159 (16.35%)		
occurrences (all)	26		
Blood alkaline phosphatase increased			

subjects affected / exposed	17 / 159 (10.69%)		
occurrences (all)	17		
Blood bilirubin increased			
subjects affected / exposed	16 / 159 (10.06%)		
occurrences (all)	16		
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Amylase increased			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Bilirubin conjugated increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood albumin decreased			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Blood albumin increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood glucose increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood potassium decreased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood sodium decreased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood thyroid stimulating hormone increased			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood urea increased			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
C-reactive protein increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood creatinine increased			
subjects affected / exposed	7 / 159 (4.40%)		
occurrences (all)	7		
cell marker increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Gamma-glutamyltransferase increased			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Heart rate increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
International normalised ratio increased			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Lipase increased			
subjects affected / exposed	6 / 159 (3.77%)		
occurrences (all)	6		
Liver function test increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Lymphocyte count decreased			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Platelet count decreased			

subjects affected / exposed occurrences (all)	6 / 159 (3.77%) 6		
Weight decreased subjects affected / exposed occurrences (all)	7 / 159 (4.40%) 7		
Blood cholesterol increased subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed occurrences (all)	8 / 159 (5.03%) 8		
Contusion subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Fall subjects affected / exposed occurrences (all)	2 / 159 (1.26%) 2		
Limb traumatic amputation subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Rib fracture subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Toxicity to various agents subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Upper limb fracture subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	2 / 159 (1.26%) 2		
Pericardial effusion			



subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Nervous system disorders			
Headache			
subjects affected / exposed	11 / 159 (6.92%)		
occurrences (all)	11		
Amnesia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Hypoaesthesia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Neuropathy peripheral			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Peripheral sensory neuropathy			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Seizure			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Visual field defect			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	42 / 159 (26.42%)		
occurrences (all)	42		
Anaemia of malignant disease			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Increased tendency to bruise			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Leukocytosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Myelosuppression			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Neutropenia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Thrombocytopenia			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Diplopia			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Lacrimation increased			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Uveitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Vision blurred			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	8 / 159 (5.03%)		
occurrences (all)	8		
Constipation			
subjects affected / exposed	24 / 159 (15.09%)		
occurrences (all)	24		
Diarrhoea			
subjects affected / exposed	13 / 159 (8.18%)		
occurrences (all)	13		
Nausea			
subjects affected / exposed	23 / 159 (14.47%)		
occurrences (all)	23		
Vomiting			
subjects affected / exposed	12 / 159 (7.55%)		
occurrences (all)	12		
Abdominal pain			
subjects affected / exposed	21 / 159 (13.21%)		
occurrences (all)	21		
Hiatus hernia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Large intestine polyp			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Melaena			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Mouth haemorrhage			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Portal hypertensive gastropathy			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		

Proctalgia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Stomatitis			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Toothache			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Abdominal discomfort			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Abdominal distension			
subjects affected / exposed	6 / 159 (3.77%)		
occurrences (all)	6		
Abdominal pain upper			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Anal haemorrhage			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Angular cheilitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Colitis			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Dry mouth			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Duodenal ulcer			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		

Duodenitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Dyspepsia			
subjects affected / exposed	7 / 159 (4.40%)		
occurrences (all)	7		
Enterocolitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Eructation			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Flatulence			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Gastritis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Gingival bleeding			
subjects affected / exposed	7 / 159 (4.40%)		
occurrences (all)	7		
Haematochezia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Haemorrhoids			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		

Hepatobiliary disorders			
Biliary obstruction			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Cholangitis			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Cholelithiasis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hepatitis			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Hyperbilirubinaemia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Jaundice			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Jaundice cholestatic			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Liver disorder			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Liver injury			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	29 / 159 (18.24%)		
occurrences (all)	29		
Rash			
subjects affected / exposed	20 / 159 (12.58%)		
occurrences (all)	20		
Rash macular			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Acanthosis nigricans			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Actinic keratosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Decubitus ulcer			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Dermatitis			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Dermatitis acneiform			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Dermatitis allergic			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Dermatitis bullous			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Dry skin			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Eczema			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Eczema asteatotic			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Rash pruritic			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Scab			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Seborrhoeic dermatitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Skin exfoliation			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Skin mass			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Skin ulcer			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Toxic skin eruption			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Urticaria			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Erythema			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Erythema nodosum			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hyperhidrosis			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	1		
Hyperkeratosis			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Intertrigo			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Keratosis pilaris			



subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Lichenoid keratosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Milia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Rash maculo-papular			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Night sweats			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Pigmentation disorder			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Psoriasis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Azotaemia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Chromaturia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Haematuria			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Nephritis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		

Nocturia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Renal failure			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Renal injury			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Urinary incontinence			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Urinary retention			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	9 / 159 (5.66%)		
occurrences (all)	9		
Adrenal insufficiency			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		
Hypercalcaemia of malignancy			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hyperthyroidism			
subjects affected / exposed	7 / 159 (4.40%)		
occurrences (all)	7		
Hypophysitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hypopituitarism			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	11 / 159 (6.92%)		
occurrences (all)	11		
Spinal pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Arthralgia			
subjects affected / exposed	10 / 159 (6.29%)		
occurrences (all)	10		
Bone pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Muscle discomfort			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Muscle spasms			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Musculoskeletal stiffness			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Myositis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Neck pain			

subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Sarcopenia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Infections and infestations			
Bacteraemia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Bacterial vaginosis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Biliary tract infection			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Bronchitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Candida infections			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Device related infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Gingivitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Herpes oesophagitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		

Herpes zoster			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Infection			
subjects affected / exposed	2 / 159 (1.26%)		
occurrences (all)	2		
Nasopharyngitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Osteomyelitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Periodontitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Pyuria			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Skin infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Staphylococcal skin infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	4 / 159 (2.52%)		
occurrences (all)	4		

Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	34 / 159 (21.38%) 34		
Hypoalbuminaemia subjects affected / exposed occurrences (all)	16 / 159 (10.06%) 16		
Hyponatraemia subjects affected / exposed occurrences (all)	11 / 159 (6.92%) 11		
Electrolyte imbalance subjects affected / exposed occurrences (all)	2 / 159 (1.26%) 2		
Hyperammonaemia subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Hypercalcaemia subjects affected / exposed occurrences (all)	5 / 159 (3.14%) 5		
Hyperglycaemia subjects affected / exposed occurrences (all)	5 / 159 (3.14%) 5		
Hyperkalaemia subjects affected / exposed occurrences (all)	4 / 159 (2.52%) 4		
Hypernatraemia subjects affected / exposed occurrences (all)	1 / 159 (0.63%) 1		
Hypocalcaemia subjects affected / exposed occurrences (all)	3 / 159 (1.89%) 3		
Hypokalaemia			

subjects affected / exposed	5 / 159 (3.14%)		
occurrences (all)	5		
Hypomagnesaemia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Hypophosphataemia			
subjects affected / exposed	3 / 159 (1.89%)		
occurrences (all)	3		
Hypoproteinaemia			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Steroid diabetes			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		
Type 1 diabetes mellitus			
subjects affected / exposed	1 / 159 (0.63%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 August 2019	<ul style="list-style-type: none"><li>• To clarify eligibility criteria of the study population.</li><li>• To modify non-serious adverse event of special interest (AESI) reporting.</li><li>• To include separate consent forms for treatment after initial and confirmed progressive disease.</li><li>• To revise the laboratory assessments.</li><li>• To include exploratory analysis of tumor shrinkage per biliary tract cancer (BTC) subtype.</li></ul>
10 October 2019	To clarify exclusion criteria of the study population and the management of immune-related adverse event and bleeding events during study intervention.
20 October 2020	<ul style="list-style-type: none"><li>• Provide sufficient survival follow up data collection for participants with long-term benefit.</li><li>• Minor text revisions are made for clarity, readability, consistency of language across the development program, and compliance with current Sponsor guidelines.</li></ul>
22 June 2021	<ul style="list-style-type: none"><li>• The risk reclassification was based on in-depth analysis of a pooled safety dataset of N = 765 subjects who received M7824 monotherapy at 1200 mg Q2W. The information on the number of subjects treated with M7824 is provided in the IB.</li><li>• Infusion-related reactions are reclassified from "important identified risk" to "identified risk" for M7824.</li><li>• Skin Adverse Events have been renamed to TGF-<math>\beta</math> Inhibition Mediated Skin Reactions.</li><li>• Term "treatment-related anemia events" has been revised to "anemia" and reclassified from "important potential risk" to "important identified risk" for M7824.</li><li>• Bleeding events are reclassified from "potential risk" to "important identified risk" for M7824.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported